Nucleic acid therapy in pediatric cancer

Area of Science:

• Oncology
• Molecular Biology
• Biotechnology

Background:

• Cancer treatment has advanced with surgery, radiotherapy, chemotherapy, and immunotherapies.
• Nucleic acid-based drugs, including siRNA, ASO, and mRNA, offer targeted therapeutic strategies.
• Despite progress, pediatric cancers remain a significant cause of mortality in children.

Purpose of the Study:

• To review the current landscape of nucleic acid therapy in pediatric cancers.
• To highlight the potential of nucleic acid therapeutics to improve outcomes for young cancer patients.
• To emphasize the need for further research and development in this area.

Main Methods:

• Literature review of preclinical and clinical studies on nucleic acid therapy for pediatric cancers.
• Analysis of approved nucleic acid therapeutics and ongoing clinical trials.
• Synthesis of information on mechanisms of action and therapeutic potential.

Main Results:

• Nucleic acid therapeutics have demonstrated efficacy in targeting specific protein expressions for cancer treatment.
• Several nucleic acid drugs are approved for rare and genetic diseases, with many more in clinical trials for various cancers.
• The application of nucleic acid therapy in pediatric cancers is an emerging field with significant potential.

Conclusions:

• Nucleic acid therapy represents a promising frontier for improving pediatric cancer treatment efficacy.
• Further investigation into nucleic acid therapeutics is crucial for enhancing survival rates and quality of life in children with cancer.
• Developing targeted nucleic acid-based strategies is essential to address the unmet needs in pediatric oncology.